IAVI T001

IAVI T001

Phase:
I
Status:
Ongoing
Strategies:
Passive Immunization
Candidates:
PGT121
Countries:
USA
Volunteers:              63
Partners:
Beth Israel Deaconess Medical Center, Ragon Institute of MGH, MIT and Harvard
 
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral efficacy of the PGT121 monoclonal antibody for HIV prevention and therapy. PGT121 mAb is a recombinant human IgG1 monoclonal antibody that targets a V3 glycan-dependent epitope region of the HIV envelope protein. PGT121 mAb was chosen for this study because it is potent, neutralizes a wide array of HIV viruses, and can prevent and treat simian-human immunodeficiency virus (SHIV) in rhesus monkeys.
ClinicalTrials.gov Identifier: NCT02960581